Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
NEWTON, Mass., Dec. 4, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that Justin A. Renz, Executive Vice President and...
-
- Presentation to Include Discussion of Selinexor as Single-Agent and in Combination to Treat Hematological Malignancies - - Webcast Event Scheduled for Monday, December 8, 2014 at 8:30 p.m. PST...
-
NEWTON, Mass., Dec. 1, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that its lead drug candidate, Selinexor (KPT-330),...
-
- Selinexor Synergy with DNA Damage Inducing Treatments Provides Potential for Improved Clinical Outcomes - - XPO1 Occupancy Assay Developed to Evaluate Selinexor Binding to its Target and...
-
- Reported Positive Phase 1 Clinical Data Demonstrating Early Signs of Activity for Selinexor in Several Solid Tumor Settings - - Initiated SIRTT, an Additional Registration-Directed Trial for...
-
NEWTON, Mass., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the initiation of its Phase 2 study of Selinexor...
-
NEWTON, Mass., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that clinical and pre-clinical data for its lead...
-
NEWTON, Mass., Nov. 5, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today that Michael G. Kauffman, MD, PhD, Chief Executive Officer of...
-
NEWTON, Mass., Nov. 4, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the appointment of J. Scott Garland, Senior Vice...
-
NEWTON, Mass., Oct. 30, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company today announced it will report third quarter 2014 financial results...